biomaterials-congress-2019-keynote

4 / 7

Biomaterials Congress 2019 Materials Science and Nanotechnology | Volume 3
Page 17
June 19-20, 2019 | Dublin, Ireland
BIOMATERIALS,
CELLULAR AND TISSUE ENGINEERING
3rd International Conference on
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
YEARS
SAFETY AND CHALLENGES OF SCAFFOLD
USED IN TISSUE ENGINEERING
Tissue Engineering is a rapidly growing area having multidisciplinary sci-
ence and expertise. This interdisciplinary engineering has attracted much
attention as a new therapeutic means that may overcome the drawbacks in-
volved in the current artificial organs and organ transplantation, that have
also aiming at replacing lost or severely damaged tissues or organs.TheTissue
Engineered Medical Products (TEMP) comprise the biological components
such as the cells, tissue, cellular products, biomaterials, biologics or synthetic
materials used in combination. Typically the cells are seeded onto a substrate
and allowed to proliferate until an adequate amount of tissue or cells are
available for transplant to the patient and the ‘device’is generally considered
as a combination product. In vitro and in vivo models to evaluate the safety
or compatibility of the cellular materials are very specialized and specific. The
evaluations include assessment of cytotoxicity, cell adhesion, growth and
proliferation, expression of functional phenotype of the cells under consid-
eration etc. However, the combination products need more evaluation on its
biocompatibility aspect. The substrate or matrix materials used to ‘seed’ the
cellular materials are subjected to routine materials/device evaluations. Typi-
cally these products are considered as implants that may degrade or absorb,
leaving only the cellular component behind. Or in other cases, the substrate
or protective polymer is considered a permanent implant that allows the cells
to function without rejection. The polymer matrix or substrate is subject to
biological/safety evaluations. The types and degree of in vitro and in vivo as-
says depend on the nature of the product. The safety from contamination
by potentially infectious adventitious agents, toxicity, genotoxicity, biomate-
rials compatibility, immunogenicity and inflammatory responses are typical
for tissue engineered products. The ASTM is making a concerted effort to
establish standards and guidelines for the entire field of tissue-engineered
medical products. Safety, consistency and functionality of biomaterials used
as matrices, scaffolds and immobilizing agents in tissue-engineered medical
products are of concern. The evaluation of cellular materials fall outside the
range of ISO 10993, EU and other international standards. The details of the
safety and challenges will be discussed during the presentation.
PV Mohanan, Mater Sci Nanotechnol 2019, Volume 3
PV Mohanan obtained BSc, MSc from Calicut Uni-
versity and PhD from Kerala University. He was
a JSPS Post-Doctoral Fellow at the University of
Tsukuba, Japan in the field of Neurotoxicity. He
joined at Sree Chitra Tirunal Institute for Medi-
cal Sciences and Technology (SCTIMST) in 1989
and has spent 30 years of professional life here.
As a toxicologist he has been intimately associ-
ated with all the medical devices/technologies
developed at SCTIMST. Currently he heads the
Division of Toxicology. He is a Visiting Professor
and Visiting Researcher at Tokyo University, Ja-
pan and a Certified Biological Safety Specialist.
He received lifetime achievement award from
the Society of Toxicology, India for the outstand-
ing contribution in the field of toxicology. He has
been teaching toxicology to Postgraduates and
guiding research scholars. Development of Hu-
man-on-a-chip is a newmega project, apart from
several other funded research projects. He got a
Patent for an ELISA kit for the measurement of
pyrogenicity. He made significant contributions
for the development of medical device regula-
tions in India.
PV Mohanan
Sree Chitra Tirunal Institute for Medical Sciences and Technology, India
BIOGRAPHY